Home / Innere Medizin / Leena Gandhi on the results of KEYNOTE-189

Leena Gandhi on the results of KEYNOTE-189

In the study, the combination of chemotherapy with pembrolizumab performed significantly better in terms of ORR, PFS and OS.

Cookies aktivieren

Um das Video anzusehen, müssen Sie Statistikcookies akzeptieren.

Einstellungen verwalten

Leena Gandhi, MD, PhD, associate professor in the Department of Medicine and director of Thoracic Medical Oncology Program, Perlmutter Cancer Center at NYU Langone Health speaks about the results of KEYNOTE-189 that showed that the combination of immuntherapy and chemotherapy was significantly better in terms of ORR, PFS and OS compared with chemotherapy alone in patients with newly diagnosed metastatic NSCLC.

Reference:
Gandhi L et al., abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC

Jetzt für unsere Newsletter anmelden!

In unseren Newslettern informieren wir Sie regelmäßig über Neuigkeiten aus der Welt der Medizin, neue Fortbildungen und fachspezifische Inhalte.

LOGIN